Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.41 |
| ▸ | ECE1 | P42892 | 5/20 | 0.40 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | SDCBP | O00560 | 1/20 | 0.37 |
| ▸ | SDC2 | P34741 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1052259 | 1.00 | ACE (0.41) | ACEECE1ITGB2ICAM1ITGAL | |
| SCHEMBL935379 | 1.00 | ACE (0.41) | ACEECE1ITGB2ICAM1ITGAL | |
| SCHEMBL935380 | 1.00 | ACE (0.41) | ACEECE1ITGB2ICAM1ITGAL | |
| SCHEMBL936102 | 0.90 | ECE1 (0.46) | ACEECE1ITGB2ICAM1ITGAL | |
| SCHEMBL936100 | 0.90 | ECE1 (0.46) | ACEECE1ITGB2ICAM1ITGAL | |
| SCHEMBL1055888 | 0.90 | ECE1 (0.46) | ACEECE1ITGB2ICAM1ITGAL | |
| SCHEMBL935339 | 0.89 | GPR84 (0.41) | ECE1ITGB2ICAM1ITGALPOLB | |
| SCHEMBL957431 | 0.89 | GPR84 (0.41) | ECE1ITGB2ICAM1ITGALPOLB | |
| SCHEMBL955533 | 0.89 | GPR84 (0.41) | ECE1ITGB2ICAM1ITGALPOLB | |
| SCHEMBL935823 | 0.89 | ECE1 (0.45) | ACEECE1ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011010748-A1 | INDOLE DERIVATIVE AND SALTINESS-STRENGTHENING AGENT CONTAINING THE DERIVATIVE | 味の素株式会社 (JP) | 2011-01-27 | — | — | WO | disclosed |